Suzhou Zelgen Stock Hits Day Low of CNY 84.52 Amid Price Pressure

Suzhou Zelgen Biopharmaceuticals Co., Ltd. experienced a significant decline today, with the stock dropping by 11.04% and reaching an intraday low of CNY 84.52. This performance stands in contrast to the China Shanghai Composite, which fell by only 1.26% on the same day. Over the past week, Suzhou Zelgen has seen a decrease of 6.31%, while its monthly performance reflects a decline of 7.89%. Despite these short-term challenges, the company has shown resilience over the past year, achieving a return of 28.41%, outperforming the broader market's 22.49% gain. However, the stock's year-to-date performance is down by 7.59%. Financial metrics indicate that Suzhou Zelgen is grappling with management efficiency issues, as evidenced by a return on capital employed (ROCE) of 0% and a negative net worth. The company has reported consistent losses, raising concerns about its sustainability without fresh capital or profitability. Despite these hurdles, the firm has declared positive results for the last four consecutive quarters, with net sales peaking at CNY 217.79 million.